BiotechTube
Spur Therapeutics

Spur Therapeutics

London, United Kingdom· Est.
spurtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Spur Therapeutics is a UK-based, clinical-stage biotech pioneering optimized gene therapies. Its lead candidate, FLT201, is an AAV gene therapy for Type 1 Gaucher disease, with promising two-year Phase 1/2 data presented in 2026. The company's strategy involves leveraging its platform to expand from rare diseases into larger indications like Parkinson's, dementia, and cardiovascular conditions, aiming for transformational, one-time treatments.

Rare DiseaseNeurologyCardiovascular

Technology Platform

Integrated gene therapy platform focusing on optimizing gene expression, vector packaging, and delivery systems for AAV-based therapies.

Opportunities

Validating its platform in Gaucher disease could enable expansion into large, underserved markets like Parkinson's and dementia with multi-billion dollar potential.
Positive long-term data for FLT201 may attract partnership deals or M&A interest from larger pharmaceutical companies seeking gene therapy assets.

Risk Factors

High clinical development risk, especially in complex neurological indications like dementia.
Heavy reliance on future financing rounds as a pre-revenue private company, and intense competition in both rare disease and prevalent disease gene therapy spaces.

Competitive Landscape

In Gaucher disease, competes against established enzyme replacement therapies (e.g., Sanofi, Takeda) and substrate reduction therapies. In broader neurological and cardiovascular gene therapy, faces competition from large biopharma (e.g., Roche, Novartis, Pfizer) and numerous clinical-stage biotechs targeting similar indications with various modalities.

More companies in United Kingdom →